论文信息 - ASO Author Reflections: Malignant Peritoneal Cytology, Adjuvant Therapy Choice, and Survival in Advanced Endometrial Cancer - 字舞流文

ASO Author Reflections: Malignant Peritoneal Cytology, Adjuvant Therapy Choice, and Survival in Advanced Endometrial Cancer

K. Matsuo | M. Klar | S. Matsuzaki | H. Miller

[1] P. Harter,et al. Association Between Adjuvant Therapy and Survival in Stage II–III Endometrial Cancer: Influence of Malignant Peritoneal Cytology , 2021, Annals of Surgical Oncology.

[2] K. Matsuo,et al. Proposal of an endometrial cancer staging schema with stage-specific incorporation of malignant peritoneal cytology. , 2020, American journal of obstetrics and gynecology.

[3] P. Harter,et al. Malignant peritoneal cytology: Areas of unmet need for evidence. , 2020, European journal of cancer.

[4] Matthew P. Goetz,et al. NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[5] S. Pecorelli. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium , 2009 .